CADL — Candel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1841387 ·
Last close
$12.86
Market Cap
$984.03M
52W High
$13.82
52W Low
$7.91
ADV30
1,278,185
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,262,000 | -8,861,000 | 201,920,000 | 194,834,000 | 63,891,000 |
| Dec 2025 | 0 | — | -15,663,000 | -29,496,000 | 125,195,000 | 119,731,000 | 73,273,000 |
| Sep 2025 | 0 | — | -13,207,000 | -11,269,000 | 93,598,000 | 86,963,000 | 13,474,000 |
| Jun 2025 | 0 | — | -11,177,000 | -4,796,000 | 105,968,000 | 100,687,000 | 15,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,732,000
Investing CF
$-1,232,000
Financing CF
$151,783,000
CapEx
$-1,259,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-239,248,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-51,045,000
Pretax Income TTM
$-54,422,000
Interest Exp TTM
$3,377,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,177,000 | -38,182,000 | 125,195,000 | 73,273,000 | — | -38,311,000 |
| Dec 2024 | 0 | -33,371,000 | -55,177,000 | 106,866,000 | 40,539,000 | — | -27,023,000 |
| Dec 2023 | 0 | -38,391,000 | -37,939,000 | 41,201,000 | 28,456,000 | — | -34,244,000 |
| Dec 2022 | 125,000 | -34,674,000 | -18,794,000 | 77,691,000 | 29,977,000 | — | -31,419,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.62
Max Pain — expiry 2027-01-15
max pain strike: $9.00 · spot: $13.65 · call oi: 3,404 · put oi: 1,365
Expected Move to 2027-01-15:
±$6.75
(49.45%) —
implied range
$6.90 –
$20.40
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLDB | Solid Biosciences Inc. | $982.18M | $9.16 | — |
| DBVT | DBV Technologies S.A. | $888.64M | $14.14 | — |
| SANA | Sana Biotechnology, Inc. | $1.13B | $3.78 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $850.21M | $15.39 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.18B | $13.77 | — |
News headlines (Yahoo Finance, 1h cache)
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
2026-08-13 19:27 · Yahoo
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
2026-08-12 19:08 · Yahoo
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
2026-08-12 17:04 · Yahoo
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
2026-08-03 12:05 · Yahoo
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
2026-06-30 16:27 · Yahoo
Candel Therapeutics Designates Mark Sims as CCO
2026-06-25 19:53 · Yahoo
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
2026-06-05 10:23 · Yahoo
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
2026-06-02 12:05 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
2026-08-18 14:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.